Study type: Biochemistry2004
Cannabinoid pillar · varin series
Cannabigerovarin (CBGV).
Has CBGV been tested in people for any condition?
No. CBGV has been tested in cells and mice, never in a person, and no human trial, pharmacokinetic study or safety study of CBGV isolate has been published for any outcome. evidence state: Catalogue in progress
Trim two carbons from CBG's side chain and you get CBGV, its propyl homolog: the same cannabigerol scaffold on a three-carbon tail. The molecule has a research record, built in cell assays and in mice. What it has never had is a person. So whatever you hear about what CBGV does in the body, the source is a mouse or a dish of cells.
Evidence library·21 studies·updated 9 August 2026·How we check
On this page13 sections
Origin & biosynthetic role
The varin cousin of CBG.
Cannabis runs two assembly lines side by side. The busy one turns out pentyl cannabinoids, with a five-carbon side chain; a quieter one turns out varin cannabinoids, with three. CBGV is what the varin line makes where the pentyl line makes CBG: the same geranyl core on a shorter tail. Its acid, CBGVA, is the varin analog of CBGa, and decarboxylation turns it into neutral CBGV. All of that is settled chemistry. A family resemblance, though, tells you nothing about effects.
Divarinolic acid + GPP
substrate
CBGVA
varin precursor
CBGV
neutral form
Varin series: enzymes assemble the acid, then decarboxylation (heat / time) removes CO₂.
Olivetolic acid + GPP
substrate
CBGa
pentyl precursor
CBG
neutral form
Pentyl series: the verified pathway CBGV is thought to parallel, and the basis for the analogy.
The two carbons, drawn: CBG beside CBGV
Cannabigerol CBG
- Formula
- C₂₁H₃₂O₂
- PubChem
- CID 5315659
The two extra carbons at the end of the side chain: five in the pentyl form, three in the varin.
Cannabigerovarin CBGV
- Formula
- C₁₉H₂₈O₂
- PubChem
- CID 59444407
No shading on this side: it is the smaller structure, and every atom in it also appears in the other drawing.
Skeletal drawings generated with RDKit from the PubChem structures cited above; shaded atoms are those absent from the other drawing. Chemical identity only: nothing here describes an effect.
Figure K · the varins
Pentyl vs. varin — CBGV & CBDV
Ask the supplier: six questions about CBGV.
Six questions to put to a supplier, each followed by the position the registry or this compound's page already holds, in its own words. The questions ask what the supplier states; none asks what anyone should take. Informational only, not medical or legal advice.
- 1What human data does the supplier cite for the product?
- The pillar's answer is none: “Nobody has published a trial of CBGV's effects in people”. Any human claim on the label has no source to point at.On the CBGV page →
- 2How many milligrams of CBGV per serving, and against what?
- There is no human study to size the figure against: no trial in people, and no “dedicated human pharmacokinetic or dose-ranging study of CBGV isolate”.On the CBGV page →
- 3On what basis does the label say non-intoxicating?
- The pillar's specimen row hedges it: “Probably not; inferred from structure, untested”. A label that states it flat is stating more than the site does.On the CBGV page →
- 4What safety data does the supplier hold?
- The pillar records the gap: not characterised in people, “with no human safety, tolerability or drug-interaction data at all”.On the CBGV page →
- 5Is the figure on the certificate CBGV or its acid, CBGVA?
- They are different rows: CBGVA is the varin analog of CBGa, and “decarboxylating CBGVA would give neutral CBGV”. Ask which the assay measured.On the CBGV page →
- 6Does the supplier cite a receptor or target profile for CBGV?
- The pillar cites the in-vitro screens and grades none of them: “we assign CBGV no target profile”. A profile on a spec sheet is the supplier's, not the registry's.On the CBGV page →
Take the answers to the paperwork: Read a COA, then test the label wording. How the site grades what it holds is on How we grade.
The knowledge boundary
What is established about CBGV, and what is not
The chemistry is solid. Past it, almost everything is open, and the largest open question is the simplest one to ask: what happens when a person takes it?
Established
- ✓Chemical identityC₁₉H₂₈O₂ (≈ 288.4 g/mol). It carries a propyl (C₃) side chain where CBG carries a pentyl (C₅) one.
- ✓Biosynthetic relationshipIts acid form, CBGVA, is the varin analog of CBGa, so decarboxylating CBGVA would give neutral CBGV. The varin series is thought to run parallel to the pentyl pathway, an inference drawn from the pentyl-series studies we hold; our registry contains no CBGV-specific biosynthesis study.
Not yet established
- —Any human evidenceNobody has published a trial of CBGV's effects in people, or a dedicated human pharmacokinetic or dose-ranging study of CBGV isolate. Beyond its chemistry, everything on this page comes from cells and mice, which makes this the biggest gap in its record.
- —A graded target profileCBGV has turned up in in-vitro receptor and ion-channel screens, cited below. None of that pharmacology is a graded record in our registry, so we assign CBGV no target profile.
- —Independent replicationEach CBGV observation rests on roughly one lab report, and the CB1/CB2 work has authors employed by a cannabinoid supplier. No unaffiliated group has reproduced any of it.
- —Safety profileNot characterised in people, with no human safety, tolerability or drug-interaction data at all. Treat CBGV as a research-stage compound.
- —Non-intoxicating statusProbably non-intoxicating, by inference from the cannabigerol scaffold it shares with CBG. Nothing in our registry verifies this for CBGV.
The gap is human data
Two different gaps hide behind any talk of “missing CBGV evidence”, and they are worth keeping apart. The first is about people. CBGV has been studied, in receptor and ion-channel screens and in mice, and nobody has yet studied it in a person: no trial of its effects, and no dedicated human pharmacokinetic or dose-ranging study of CBGV isolate. The second is about us. None of that preclinical work is yet a graded record in our registry, so the papers appear further down with their disclosures and without an evidence grade. One gap is a fact about the science; the other is a fact about our grading.
Figure L · reference cards
CBGV & CBDV — evidence-graded data cards
What has been tested
The preclinical CBGV record.
Four published studies have put CBGV through its paces by name, every one of them in cells or mice. Start with what was actually tested, the species and the preparation, before you read any result. Most misreadings of this literature begin with a rat channel taken for a human receptor, or a dish of cells taken for a patient.
Cited, but not graded
The four papers are published and checkable, and they are not yet graded entries in the CBG Atlas registry. That keeps them off our evidence ladder, and no grade on this page rests on them, much as the published human pharmacokinetic work sits off the ladder on the CBG monograph. When one of them joins the registry, it will carry a grade like any other record.
2020
Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors
What was tested: Human CB1 and CB2 receptors expressed in a lab cell line (heterologous expression). Cells in a dish, start to finish.
Across four functional read-outs, each phytocannabinoid tested acted like an agonist on its own and like an inverse agonist once a selective receptor agonist was present. Among the compounds screened, “CBGV displayed enhanced potency in many of the functional outputs”. The signalling was biased: which read-out a compound drove tracked how it bound. All of it is receptor behaviour in a controlled assay: it measures nothing in a person and supports no claim about what CBGV does in the body.
Caveat: Conflict of interest: two of the authors are employed by Phytoplant Research S.L., a cannabinoid supplier. Read the result with that affiliation in mind.
Off-registry · no evidence grade
2011
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
What was tested: Human TRPV1, in a calcium assay in transfected cells.
CBGV first stimulated and then desensitised human TRPV1, which makes this one of very few CBGV observations made on a human receptor rather than a rodent one. Desensitisation means a second exposure draws a weaker response than the first: a description of how the channel behaved in the assay, with no benefit implied.
Registry status: The paper sits in our evidence registry, graded for its CBG result: TRPV1/TRPV2 desensitiser, TRPM8 antagonist. The CBGV observation rides along in the same publication without a grade of its own, so it appears here in prose, ungraded.
In the registry, graded for a different finding
2011
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
What was tested: Rat recombinant TRPV3 and TRPV4 channels expressed in HEK-293 cells. Rat channels in a dish, with no whole animal involved.
CBGV and CBGA “were significantly more efficacious at desensitizing this channel [TRPV3] to the action of carvacrol than at activating it”. TRPV4 showed the same pattern: “CBGA, CBGV, cannabinol and cannabigerol were significantly more efficacious at desensitizing this channel to the action of 4α-PDD than at activating it”. Put simply, in this assay CBGV tended to quiet these channels more than it switched them on.
Caveat: Published 2011, though one external summary of this work dated it 2012. Species matters more than the year: a result at the rat channel stays a rat result until someone repeats it at the human one.
Off-registry · no evidence grade
2022
Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain
What was tested: Lab-synthesised side-chain variants of CBG, including CBGV, tested on colorectal cancer cells in vitro and in a mouse model of chemotherapy-induced neuropathic pain.
In the mice, every side-chain length reduced chemotherapy-induced neuropathic pain by a similar amount. In the dish, the shorter chains, CBGV among them, did more to cut colorectal cancer cell viability. Neither result travels far. A well of cells is not a tumour in a patient, and a mouse pain model is not a person in pain. What the study shows is how side-chain length changes activity, and it is not evidence of benefit.
Caveat: Penn State College of Medicine; the author list declares no industry affiliation. Set it beside the glioblastoma caution below, because the two in-vitro cancer-cell results point in different directions.
Off-registry · no evidence grade
One letter apart, two molecules
CBGV is not CBGVA.
One 2021 mouse study tested CBGV and its acid, CBGVA, and got a different answer for each. One letter separates the names, and the results belong to two different molecules. Quote either column and you owe the reader the other.
| Property | CBGV, the neutral compound | CBGVA, the acid (a different molecule) |
|---|---|---|
| What it is | Cannabigerovarin, the neutral compound | Cannabigerovarinic acid, a separate molecule and the acid precursor CBGV is made from |
| In the Anderson 2021 mouse seizure screen | Did not change thresholds for hyperthermia-induced seizures at the one dose tested (100 mg/kg, intraperitoneal, given as a suspension) | One of three acids the same screen flagged as anticonvulsant (alongside CBGA and CBDVA) |
| What the result supports | “No effect at the dose tested,” and nothing wider: one dose, one model, one formulation. A suspension limits how much compound reaches the circulation, which leaves open whether CBGV is inactive. | A preclinical signal from one mouse screen, in a paper whose lead compound, CBGA, was anticonvulsant in one test and proconvulsant in another. The authors themselves conclude that liabilities would need to be overcome. |
| Does the result carry across? | No. The acid and the neutral form are different molecules that the body handles differently, so a finding about one says nothing about the other. | No. Both columns are mouse results, and neither says anything about either molecule in a person. |
| Human evidence | None published | None published |
How to read the table
Read the left column narrowly. “No effect at the dose tested” is a statement about one experiment, and it leaves the question of whether CBGV is active open in both directions: one dose, one model, and a suspension, which limits how much compound reaches the circulation. The right column belongs to a different molecule and stays in its own column. Both columns describe mice, neither says anything about either compound in people, and CBG Atlas claims no seizure-related property for CBGV or CBGVA. This is educational information, not medical advice.
2021
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
What was tested: Mouse models of epilepsy: a screen of phytocannabinoids against seizure thresholds.
The paper behind both columns of the table above. Its title announces the divergence: one compound in it was anticonvulsant in one test and proconvulsant in another. Its CBGV and CBGVA results live in the table, where they cannot be read apart.
Caveat: Quote the CBGV and CBGVA results together or not at all. Either half on its own misleads.
Off-registry · no evidence grade
2019
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome
What was tested: Pharmacokinetics of six phytocannabinoid acids, CBGVA among them, given intraperitoneally to mice. Animal data on the acid alone.
The study characterised CBGVA's pharmacokinetics alongside five other phytocannabinoid acids. As a class, the acids reached the brain poorly, and for CBGVA that is as far as the paper goes.
Caveat: Its subject is the acid and its measure is exposure in mice. Anyone after a CBGV pharmacokinetic profile will have to keep looking.
Off-registry · no evidence grade
CBGV vs CBG
A shorter chain and a much thinner file.
Put CBGV beside its pentyl parent and the chemistry lines up almost row for row. The evidence does not.
| Property | CBGV | CBG |
|---|---|---|
| Relationship | Propyl (C₃) side chain | Pentyl (C₅) side chain |
| Molecular formula | C₁₉H₂₈O₂ · ≈ 288.4 | C₂₁H₃₂O₂ · 316.48 |
| Acidic precursor | CBGVA (varin series) | CBGa (pentyl series) |
| Biosynthetic role | Varin-series counterpart of the CBG branch point, by inference from the verified pentyl pathway; not shown for CBGV | The pentyl “mother cannabinoid” |
| Characterized pharmacology | Tested in a few in-vitro screens (CB1/CB2, TRPV1, TRPV3/TRPV4). No graded registry record, so no target profile is assigned | α2-adrenoceptor, 5-HT1A, CB1, TRP channels (in vitro) |
| Human evidence | None published, on effects or on exposure | One small acute trial (Low) |
| Depth of the record | A handful of preclinical reports, mostly one lab each, none replicated by another group | Several preclinical studies and one human trial in our registry |
| Intoxicating | Probably not; inferred from structure, untested | No |
What comes next
What new evidence would change what we say about CBGV?
Three kinds of work would change what can be said about CBGV. The first is the one everything else waits on.
01
A first human study
Any study of CBGV in people, starting with tolerability and exposure. Every other question about the compound waits on this one.
02
Independent replication
Each in-vitro result so far rests on roughly one lab, and the CB1/CB2 work has authors employed by a cannabinoid supplier. An unaffiliated group reproducing any of them would turn an observation into a finding.
03
Reconciling the conflicting cell results
The colorectal and glioblastoma cell results pull in opposite directions. Work that reconciles them, or shows they answer different questions, would be worth more than another single-lab screen.
Safety & practical
What is known about CBGV safety, and what is not?
What is uncertain
CBGV is expected to be non-intoxicating, an inference from the cannabigerol scaffold it shares with CBG that has not been verified for CBGV in our registry. Beyond that one expectation, its safety profile is not characterized. There are no human safety, tolerability or drug-interaction data, and the preclinical work above set out to answer other questions. Until that changes, treat it as a research-stage compound. The cardiovascular and interaction cautions elsewhere on CBG Atlas were written for CBG and apply to CBG, not to CBGV. This is educational information, not medical advice.
Safety caution · early laboratory report · cancer treatment
What was tested: Glioblastoma cells in the lab (Harvard / Dana-Farber). Cells in a dish, and only cells. Why it counts as a caution: treatment-induced cancer-cell death went down, not up. Cannabinoids including CBGV made glioblastoma cells less likely to die under chemotherapy and radiation. They did it by lowering what the authors call apoptotic priming, meaning how close a cell already sits to its own death threshold. Whether anything similar happens in a person having cancer treatment is untested. Read it as a reason for care, never as a reason to use CBGV in cancer care: anyone undergoing cancer treatment should discuss any cannabinoid product with their oncology team. Cited by DOI while PubMed indexing catches up, and this early accepted version may change before final publication. It also sits awkwardly beside the colorectal-cell result above: one report has CBGV reducing cancer-cell viability, the other has it blunting treatment-induced cancer-cell death in a different tumour type. Two small, unreplicated lab findings pulling opposite ways describe an unsettled literature, and neither is a basis for use.
2026
Title not yet indexed in PubMed; see the DOI
Off-registry and ungraded, cited by its DOI alone, and this early accepted version may change before final publication.
Off-registry · no PMID · no evidence grade
References & further reading
Where every CBGV claim on this page comes from
The registry-graded records come first, and they cover family biosynthesis rather than CBGV. The CBGV-specific papers follow: published, checkable and ungraded.
Registry-graded: family biosynthesis (not CBGV-specific)
2004
The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L.
1996
Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.
2018
Elucidation of structure-function relationship of THCA and CBDA synthase from Cannabis sativa L.
2016
Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry
CBGV papers cited above, ungraded in our registry
Show all 7 papers with PubMed and DOI links
2020
Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors
2011
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
2011
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
2022
Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain
2021
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
2019
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome
For graded evidence, read CBGa and the CBG monograph.
Identity & origin
Show the answers 4
What is CBGV?
CBGV (cannabigerovarin) is a rare, non-intoxicating minor cannabinoid, the propyl (varin) homolog of CBG, found in trace amounts in some hemp and cannabis varieties. Chemists have its identity pinned down. Its effects in people have barely been studied.
What does CBGV (cannabigerovarin) mean?
CBGV stands for cannabigerovarin, and the name spells out the structure: the varin (V) version of cannabigerol (CBG), carrying a three-carbon propyl side chain, two carbons shorter than CBG's. Formula C19H28O2, CAS 55824-11-8: settled chemistry, and silent on what CBGV does in a person.
Where does CBGV come from — how does the plant make it?
The plant makes CBGV from its acid precursor, CBGVA (cannabigerovarinic acid), sometimes called the "varin mother acid." Heat strips CO₂ from CBGVA (decarboxylation) to give CBGV. CBGVA heads the varin branch of the plant's chemistry the way CBGA heads the main line.
Is CBGV natural or synthetic?
CBGV is natural. It occurs in trace amounts in certain hemp and cannabis chemotypes, notably some varin-rich varieties. It can be made in a lab as well, but the molecule itself comes from the plant, and commercial CBGV, rare as it is, is usually concentrated from hemp.
Psychoactivity
Show the answers 4
Does CBGV get you high?
No. CBGV is non-intoxicating, and a THC-like high isn't expected, because it lacks THC's way of activating the CB1 receptor. The conclusion rests on structure rather than on people, since no formal human study has measured CBGV's subjective effects.
Is CBGV psychoactive?
Not in the THC sense: CBGV is considered non-intoxicating and isn't known to cause a high. "Psychoactive" covers more ground, though, and whether CBGV nudges mood or alertness at all is unstudied, with verified human evidence missing either way. The question stays catalogue in progress.
What does CBGV feel like?
Nobody can say, because CBGV's subjective effects have never been studied in humans. Online descriptions of how it feels are anecdotes, unverified and unaffirmed by CBG Atlas (not medical advice).
Is CBGV active?
Only in cells so far. In laboratory (in-vitro) work, CBGV showed some activity at TRPV1/TRPV2 ion channels and on anandamide uptake (De Petrocellis 2011, PMID 21175579). Some of those measurements used an extract, and none demonstrates an effect in people; what the finding means for the body is not established.
Legality
Show the answers 4
Is CBGV legal?
It depends more on the source and the jurisdiction than on the molecule. Where hemp-derived cannabinoids under 0.3% Δ⁹-THC are permitted, CBGV generally fits that framework; elsewhere it may be restricted. A general, dated snapshot (2026-07-11), not legal advice; verify locally.
Is CBGV legal federally (2018 Farm Bill)?
Generally yes, with one significant limit. Hemp-derived CBGV in a product at or below 0.3% Δ⁹-THC by dry weight is generally federally legal as hemp under the 2018 Farm Bill. The limit is food: the FDA has not authorised cannabinoids as foods or dietary supplements, so a lawful hemp derivative can still be an unlawful food ingredient. Dated 2026-07-11; general information, not legal advice.
Is CBGV legal in my state?
That depends on your state. US state laws vary, and some restrict hemp cannabinoids more tightly than federal law does. CBGV is rarely named in statute, so it usually falls under your state's general hemp and THC rules; check the current statute. Dated 2026-07-11; informational only, not legal advice.
Is CBGV legal in the UK / EU / Canada?
As a freely sold food or supplement, generally not. The EU and UK classify extracted cannabinoids as "novel foods" that need authorisation, and CBGV has no specific authorisation. Canada regulates isolated phytocannabinoids under the Cannabis Act. The rules differ by product class and change often. Dated 2026-07-11; general information, not legal advice. Verify with official sources.
Effects & benefits
Show the answers 7
What are the benefits of CBGV?
None is established. CBGV is among the least-studied cannabinoids, with no verified human or clinical evidence for any benefit. Marketing sometimes implies it mirrors CBG, a resemblance nobody has shown (not medical advice). We report such claims without affirming them. The question stays catalogue in progress.
What is CBGV used for?
CBGV is used mainly as a rare ingredient in "minor cannabinoid" or "full-spectrum" hemp products, and as a research and reference compound. Any therapeutic use is unestablished, and with no controlled human study of CBGV published, the question is untested rather than tested and null. Wellness uses come from marketing and stay catalogue in progress. (Not medical advice.)
Does CBGV do what CBG does?
Not established: nobody has shown that it does. CBGV is CBG's varin cousin, and similar structures can still behave differently; CBGV's pharmacology has barely been studied. It is sometimes marketed as CBG-like, an unverified claim (not medical advice). CBG's profile should not be assumed to carry over. The question remains catalogue in progress.
Is there human evidence for CBGV?
No. We know of no controlled human trial of CBGV; the verified data are all in-vitro (cell-level) observations, such as activity at TRPV1/TRPV2 channels and on anandamide uptake (De Petrocellis 2011, PMID 21175579). Human safety and efficacy remain unstudied and catalogue in progress.
Has CBGV been tested in people for any condition?
No. CBGV has been tested in cells and mice, never in a person, and no human trial, pharmacokinetic study or safety study of CBGV isolate has been published for any outcome. The laboratory record (CB1/CB2, TRP channels, one mouse seizure model, side-chain structure-activity work) maps what researchers have done to CBGV. What it does in a body is still catalogue in progress.
Does CBGV help with inflammation?
No evidence supports it, and a widely repeated citation belongs to a different compound. Sellers who cite a 2015 Burstein review for CBGV's anti-inflammatory activity are citing a review of CBD: a real paper, pinned to the wrong molecule. On CBGV itself, we hold no primary evidence on inflammation in any model. A citation about another compound supports nothing.
Can CBGV help with cancer or appetite?
Neither has been studied. Our registry holds no CBGV study of either, whether a cancer model, a feeding or appetite study, or anything in people. CBGV has never been given to a person for any outcome, so both questions start with an empty record and neither claim can be called established.
Safety & side effects
Show the answers 5
Is CBGV safe?
Nobody knows yet: CBGV's safety is not established, with no human safety studies, no defined dose and no long-term data. Non-intoxicating is one claim and "proven safe" is another, and CBGV has earned only the first. Consult a qualified professional before use, especially alongside other medications (not medical advice).
What are the side effects of CBGV?
CBGV's side effects are unknown. No controlled study has documented any, and an empty record is a gap in the data rather than a clean bill of health. A product may also contain other cannabinoids or contaminants. If you experience adverse effects, stop and get advice (not medical advice).
Can you take too much CBGV?
Nobody can say, because no safe or effective dose of CBGV has been established and overdose data are missing. With any unstudied compound, more is not better, and caution is warranted. The question remains catalogue in progress; general information, not dosing or medical advice.
Does CBGV interact with medications?
Possibly, and CBGV-specific drug-interaction data are missing. Cannabinoids in general can affect drug-metabolizing enzymes, which makes interactions plausible, though unverified for CBGV. If you take any medication, check with a clinician or pharmacist before using CBGV (not medical advice).
Is there any human safety data for CBGV?
None of any kind. Tolerability, dosing and interaction studies of CBGV in people have never been run, so its safety profile is uncharacterised. Treat it as a research-stage compound: the absence of reported harms means nobody has looked.
Drug testing
Show the answers 3
Will CBGV show up on a drug test?
CBGV itself sits outside what standard drug tests look for, which is THC's metabolite (THC-COOH). The product is the risk: a hemp product can still carry trace THC, and cross-reactivity data specific to CBGV are limited. A current third-party certificate of analysis is the only way to see what a product actually contains.
Does CBGV contain THC?
No. CBGV and THC are different molecules, and pure CBGV contains no THC. Because CBGV usually comes from hemp, though, finished products may carry trace THC unless they are made from isolate. The product's certificate of analysis (COA) lists its THC content.
Can CBGV make you fail a drug test?
CBGV itself is unlikely to cause a failure, because drug tests are built to detect THC. The risk is trace THC in a hemp-derived product, so if testing matters to you, choose products whose COA shows non-detectable THC.
Usage & dosing
Show the answers 4
How do you take CBGV?
CBGV is usually taken like other hemp cannabinoids: as an oil or tincture held under the tongue, as a capsule, or in a full-spectrum product, and it can also be vaporized and inhaled. Those are the formats on offer; CBGV has no established, studied route or dose (not medical advice).
What products/forms does CBGV come in?
CBGV comes in a small range of forms, because it is rare: mostly minor-cannabinoid tinctures, "full-spectrum" or varin-blend oils, reference isolates for formulators, and the occasional vape. Standalone high-CBGV products are uncommon. Availability, potency and purity vary widely, which is why a third-party certificate of analysis (COA) matters.
How much CBGV should I take?
There is no established dose. No clinical study has identified an effective or safe amount, so CBG Atlas gives no dosing guidance, and the number on a label is the manufacturer's choice. Consult a qualified professional (not medical or dosing advice); the question remains catalogue in progress.
How long does CBGV take to work or last?
Nobody has measured it. CBGV's onset and duration are unstudied, and it has no verified effect to time in the first place. In general, inhaled and sublingual routes act sooner and swallowed forms last longer, but for CBGV the pharmacokinetic record is blank.
Comparisons
Show the answers 4
CBGV vs CBG — what's the difference?
Structurally they are near twins: CBGV simply has a shorter propyl side chain, two carbons fewer, which is the "varin" difference. The research is lopsided. CBG has verified in-vitro receptor activity and one small human trial in our registry, while CBGV remains largely uncharacterized, and near twins can still behave differently.
CBGV vs CBD — what's the difference?
They belong to different structural families: CBGV is a varin of the CBG type, and CBD is a cannabidiol-type cannabinoid. CBD has been studied extensively and has an approved epilepsy medicine, while CBGV has barely been studied. That gap leaves their effects beyond comparison on verified evidence, and the question remains catalogue in progress.
CBGV vs THCV — how do they compare?
Both are "varin" (propyl) cannabinoids, but of different types. CBGV comes from the CBG line and is non-intoxicating; THCV is the varin form of THC, with dose-dependent receptor effects. THCV has more research behind it and CBGV almost none, which puts a verified head-to-head comparison of effects out of reach.
CBGV or CBG — which should I choose?
On the evidence, CBG is the better-documented of the two: it has verified in-vitro pharmacology and one small human trial in our registry, while CBGV has barely been studied. Neither is a proven treatment for anything, so let availability and lab testing decide rather than unverified effect claims (not medical advice).
Chemistry & production
Show the answers 4
What is CBGV's chemical formula and structure?
CBGV's molecular formula is C19H28O2 (molecular weight ≈ 288.43 g/mol), with CAS 55824-11-8 and PubChem CID 59444407. Structurally, CBGV is the propyl (varin) homolog of CBG (C21H32O2): the same cannabigerol scaffold with a side chain two carbons shorter, and a chemical identity that is well established.
How is CBGV extracted or made?
By concentrating it from varin-rich hemp or cannabis with standard extraction (e.g., CO₂ or ethanol) followed by chromatographic isolation, or by decarboxylating its acid, CBGVA. Plants produce so little that high-purity CBGV is hard and expensive to obtain, though its identity and chemistry are established.
Is CBGV a varin of CBG?
Yes. CBGV is the varin (propyl-side-chain) homolog of CBG, with the same cannabigerol core and a tail two carbons shorter. It belongs to the varin series along with THCV and CBDV, and it comes from the varin branch of biosynthesis by way of its acid, CBGVA.
Does CBGV have an acid form (CBGVA)?
Yes. CBGVA (cannabigerovarinic acid, C20H28O4, CAS 64924-07-8) is CBGV's raw-plant acid form, the "varin mother acid." Heating (decarboxylation, ~110–130 °C) removes its carboxyl group as CO₂ and turns CBGVA into CBGV, so the raw plant carries the acid and heated products carry the neutral form.
Buying & trust
Show the answers 5
Where can I buy CBGV?
From a small number of specialty hemp and cannabinoid retailers and reference-chemical suppliers, usually as an isolate or in minor-cannabinoid blends. Stock is thin and inconsistent, as you would expect for a niche product. CBG Atlas endorses no brand. Buy only from vendors that publish third-party lab results.
Why is CBGV rare or expensive?
Plants make very little CBGV, and varin cannabinoids come from specific, uncommon chemotypes, so isolating usable amounts is technically demanding and low-yield. Tight supply, plus specialized extraction and purification, makes CBGV scarce and costly next to common cannabinoids such as CBD.
How do I know a CBGV product is real (COA)?
Ask for a current certificate of analysis (COA) from an accredited third-party lab. A useful one confirms that the CBGV content matches the label, reports the THC level, and screens for pesticides, solvents and heavy metals. A missing or mismatched COA is a red flag.
Is CBGV worth trying?
That's a personal call, made on very little evidence. CBGV's benefits are unproven and its effects in people barely studied, so any value is speculative (not medical advice). If you try it, choose lab-tested products and keep expectations modest.
What should I look for when buying CBGV?
Start with a third-party COA that matches the label, then compliant THC (≤0.3% Δ⁹-THC where required, or non-detect), clearly stated cannabinoid amounts, contaminant screening and sourcing the seller discloses. Health claims deserve skepticism, since CBGV's benefits are unverified (not medical advice). Testing and transparency count for more than anything on the front of the bottle.
Before you act on what you read about CBGV
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event → Compound monographs
The rest of the family.
Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.
Cannabigerol (CBG)
The mother cannabinoid. CBGa decarboxylates to CBG, and both occur in the plant. The three synthases act on CBGa, the acid, branching it into THC, CBD and CBC. CBG carries more evidence than any other compound on the platform.
Cannabigerolic acid (CBGa)
The acid CBG comes from, and the shared substrate the three branch synthases compete for. Heat decarboxylates it to CBG.
Cannabichromene (CBC)
One of the three branches off the shared CBGA substrate, and a non-intoxicating one.
Cannabinol (CBN)
Forms as THC ages and oxidises, so it builds up in stored material rather than being made by the plant directly.
Cannabidivarin (CBDV)
CBD's propyl analogue, and the varin with the largest published human trial record.
Tetrahydrocannabivarin (THCV)
THC's propyl analogue, which in laboratory work behaves differently from THC at its receptors.
Keep exploring
Its acid or neutral form
Its varin or pentyl analogue
Head-to-head